Insider

Labcorp Holdings Inc.

LH Health Care · 5 analyses · 3 expectations tracked

Labcorp reported $3.8B in revenue (+6.9% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 3 open management expectations for this company. 4 insider sales recorded. Next scheduled event: Dividend on December 11, 2026.

Mentioned in recent filings: Ukraine Tariffs

What changed

What changed

Labcorp: third-quarter earnings, operational risks, and insider trades

Labcorp Holdings Inc. filed its 10-Q report for the third quarter of 2026, reporting quarterly revenue of $3,810 million, a 6.9% increase from the previous year. The document detailed several operational risks, including those related to implementing an enterprise resource planning (ERP) system, labor relations, and animal research activities.

· Labcorp Holdings Inc.
Dividends & buybacks

Labcorp announces dividend payment

On October 21, 2026, Labcorp Holdings Inc. declared a quarterly cash dividend of $0.72 per share. The payment is scheduled for December 11, 2026, to stockholders of record as of the close of business on November 24, 2026.

· Labcorp Holdings Inc.
What changed

Labcorp warns of danger from steep CMS payment cuts and backs the RESULTS Act

Labcorp Holdings Inc. said CMS payment rates based on inaccurate data could lead to sharp annual cuts that threaten patient access to laboratory services, reaffirmed support for the bipartisan Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and said it continues to evaluate the impact of these rates on its 2027 financial guidance.

· Labcorp Holdings Inc.

Upcoming events

As announced by the companies, read by code from their press releases, 8-Ks and official feeds; each date links its announcement. Companies can change dates. Dividends: common shares only; under T+1 settlement the ex-dividend date is normally the record date. Corporate calendar →

Company history

October 2026

LABCORP HOLDINGS INC.: 12 recorded developments from 4 official sources in 2026-10.

  • 2026-10-21: Labcorp Holdings Inc. announced that its Board of Directors declared a quarterly cash dividend of $0.72 per share of common stock. Source
  • 2026-10-21: Labcorp employs nearly 71,000 people and serves clients in approximately 100 countries. Source
  • 2026-10-21: Labcorp provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients worldwide. Source
  • 2026-10-21: On October 21, 2026, Labcorp Holdings Inc. announced that its Board of Directors declared a cash dividend of $0.72 per share of common stock, payable on December 11, 2026, to stockholders of record as of the close of business on November 24, 2026. Source
  • 2026-10-28: The company supported more than 85% of new drugs and therapeutic products approved by the FDA in 2025. Source
  • 2026-10-28: The company performed more than 750 million tests for patients around the world. Source
  • 2026-10-28: The company utilizes non-GAAP "adjusted" financial measures, which it believes are useful to investors as a supplement to GAAP measures. Source
  • 2026-10-28: Transition services fees charged to Fortrea Holdings Inc. relate to administrative and IT systems support. Source
  • 2026-10-28: The company announced its results for the quarter ended September 30, 2026. Source
  • 2026-10-28: The company received FDA approval for PGDx elio tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma. Source
  • 2026-10-28: In the third quarter of 2026, the company invested $255.5 million in acquisitions and paid out $58.2 million in dividends. Source
  • 2026-10-28: The company signed agreements to acquire select assets of BioReference Health's laboratory testing businesses, the Prenatal Health testing business of Myriad Genetics, and Millennium Health. Source

September 2026

LABCORP HOLDINGS INC.: 6 recorded developments from 2 official sources in 2026-09.

  • 2026-09-22: The Company believes the payment rates are based on data that is not fully representative of the broader commercial laboratory market and would impose steep annual payment cuts that threaten patient access to laboratory services. Source
  • 2026-09-22: The Company continues to support the bipartisan Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, a bipartisan solution that would ensure the U.S. has a sustainable and innovative laboratory system. Source
  • 2026-09-22: The Company is continuing to evaluate the CMS payment rates and expects to provide additional information regarding the impact of the CMS payment rates on its 2027 financial guidance when that guidance is announced in February 2027. Source
  • 2026-09-30: Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2026 before the market opens on Wednesday, October 28, 2026. Source
  • 2026-09-30: We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. Source
  • 2026-09-30: The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients around the world. Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed October 30, 2026. SEC

LatestEarlierChange
Revenue quarter$3.8B$3.6B+6.9%
Operating income quarter$402M$397M+1.4%
Net income quarter$263M$261M+0.7%
Diluted EPS quarter$3.22$3.12+3.2%
Dividends per share quarter$0.72$0.720.0%
Operating cash flow year to date$1.2B$1B+17.0%
Cash and cash equivalents balance$262M$532M-50.8%
Long-term debt balance$5.3B$5.1B+3.3%

Next results expected around January 29, 2027 (estimate: the quarter ending about December 30, 2026 plus the 30 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $B

3.3Q4 '24*6.5%3.3Q1 '259.7%3.5Q2 '2511.2%3.6Q3 '2511.1%3.5Q4 '25*7.6%3.5Q1 '2610.8%3.7Q2 '2612.1%3.8Q3 '2610.6%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Labcorp Holdings Inc. LH$3.8B+6.9%10.6%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • Chief Financial Officer Julia Wang will speak at the UBS Global Healthcare Conference.

    Said November 4, 2026 · Period named: November 10, 2026 · Source · Our article

    Not yet checked against later reports.

  • The 2026 Biopharma Laboratory Services guidance includes a 1.3% impact from foreign currency translation.

    Said October 28, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • The 2026 Enterprise guidance includes a 0.3% impact from foreign currency translation.

    Said October 28, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
August 14, 2026Director or officer departure or appointment (8-K item 5.02)8-K

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 16, 2026Amy B. SummySale notice filed365$372.58$135,992SEC
November 10, 2026Brian J CaveneySale notice filed2,000$372.04$744,080SEC
November 4, 2026Bailey Megan D.Planned sale3,035—$1,096,121SEC
November 3, 2026Bryan T VaughnSale 10b5-1 plan notice filed306$353.70$108,232SEC
October 30, 2026Richelle P ParhamSale notice filed1,078$361.22$389,395SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock6,535,506$2,013,654,791-0.6%Q3 2026
State Street3,943,551$1,215,047,499+0.9%Q3 2026
Fidelity (FMR)3,689,552$1,136,787,772+93.7%Q3 2026
Geode Capital Management2,186,220$670,899,215-0.1%Q3 2026
Norges Bank (Norway's sovereign fund)810,093$226,826,040—Q2 2026
Wellington Management653,630$201,389,939-23.6%Q3 2026
Citadel Advisors265,420$81,778,556+650.5%Q3 2026
D. E. Shaw & Co.242,093$74,591,274+504.8%Q3 2026
Millennium Management59,429$18,310,669-73.9%Q3 2026
Two Sigma Investments7,249$2,233,489+168.5%Q3 2026
Bridgewater Associates2,654$817,724-5.1%Q3 2026
T. Rowe Price148,479$45,749+23.9%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.